At the moment, only the vaccine developed by Pfizer and BioNTech is available in the European Union. Fortunately, other competitors will soon arrive.
Moderna
What type of vaccine? It is, like Pfizer / BioNTech, a messenger RNA vaccine but it is distinguished by a much better resistance to storage. While the first vaccine must be stored at -70 ° C, that of Moderna must be kept at -20 ° C and can especially last a month in a refrigerator. The laboratory had drawn its first results just after Pfizer / BioNtech with an efficiency rate close to 95% with two injections. In details, it turns out to be slightly less convincing than the vaccine of the previous competitor (for certain populations) even if the comparisons must be taken with a grain of salt.
AstraZeneca
What type of vaccine? AstraZeneca's vaccine, developed with the University of Oxford, does not use messenger RNA technology, which makes it very easy to produce and store (especially in hot countries) and drastically lowers its manufacturing cost. The laboratory quickly published its first results after those of Pfizer and Moderna, but being much less convincing. Two protocols were carried out with very different effects and it even seems that the most effective was obtained by mistake. At the end of December, the British laboratory claims to have corrected the shooting.
Janssen
What type of vaccine? Like AstraZeneca, it is a classic vaccine based on the platform used for its Ebola vaccine. Only one dose will be needed.
CureVac
What type of vaccine? The German startup is developing a messenger RNA vaccine, similar to the vaccines from Pfizer / BioNTech and Moderna, except that it is easily stored in the refrigerator. Another advantage is that it requires a lower dosage than its competitors and therefore allows it to be produced in larger quantities.
Novavax
What type of vaccine? The American company has chosen a vaccine based on recombinant proteins, already used for influenza vaccines for example.
Sanofi / GSK
What type of vaccine? The French also relies on the technology of recombinant proteins that he already masters for an influenza vaccine.
French news: Convid19 Vaccine
Comments
Post a Comment